EnochianLogo-2000x1607px.jpg
Enochian Biosciences Announces Three Scientific Presentations on Potential HIV and HBV Cures
May 13, 2020 08:00 ET | Enochian Biosciences, Inc.
• First presentation of a novel approach to potentially cure HIV  -  An in vivo study demonstrated a 164 percent increase in engraftment of genetically modified cells Poster Presentation -...
VIR_logo_large.jpg
VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial
April 15, 2020 16:01 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, April 15, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR) today announced additional interim data from the ongoing Phase 2 trial in patients and results from the Phase...
EnochianLogo-2000x1607px.jpg
Enochian Biosciences Announces Scientific Presentation of a Novel Approach to Potentially Cure Hepatitis B Virus
December 10, 2019 07:00 ET | Enochian Biosciences, Inc.
A new gene therapy kills up to 98 percent of HBV infected cells but not uninfected cells.  Results from a commonly used mouse model to study HBV confirmed the HBV-infected cell-specific killing effect...
EnochianLogo-2000x1607px.jpg
Enochian Biosciences Expands its Infectious Disease Pipeline by Entering into an Agreement in Principle to Acquire an Exclusive License for a Novel Hepatitis B Virus Treatment
November 25, 2019 07:00 ET | Enochian Biosciences, Inc.
Agreement provides Enochian with exclusive rights to develop and commercialize a HBV treatment with a novel mechanism of actionAbstract accepted highlighting the in vivo and in vitro data from...
Assembly Biosciences to Present at the Jefferies London Healthcare Conference
November 08, 2017 07:00 ET | Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Assembly Biosciences Announces Pricing of $60 Million Offering of Common Stock
November 02, 2017 00:40 ET | Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB) (“Assembly” or the “Company”), a clinical-stage biotechnology company advancing a new class of oral...
Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development
September 25, 2017 07:00 ET | Assembly Biosciences, Inc.
INDIANAPOLIS, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
Assembly Biosciences Announces September Conference Participation
August 31, 2017 07:00 ET | Assembly Biosciences, Inc.
INDIANAPOLIS, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...
hepion.png
ContraVir Pharmaceuticals to Present at BIO-Europe Spring 2017
March 14, 2017 06:00 ET | ContraVir Pharmaceuticals Inc
EDISON, N.J., March 14, 2017 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral...
Assembly Biosciences to Present Data on ABI-H0731 at AASLD 2016 Liver Meeting
November 11, 2016 08:00 ET | Assembly Biosciences, Inc.
INDIANAPOLIS, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of...